Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Comments

Loading...

Nova Mentis Life Science Corp

NMLSFOTC

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$0.0309

At close: Nov 30, 9:29 AM EDT

$0.0151

-0.02-51.13%

After Hours: Nov 30, 9:29 AM EDT

Nova Mentis Life Science Corp (NMLSF) Forecast

News

Earnings Nova Mentis Life Science Corp (NMLSF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest news for Nova Mentis Life Science Corp (OTC:NMLSF) Stock

Nova Mentis Life Science Corp Stock (OTC: NMLSF)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Monday, April 24, 2023

Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
Lara Goldstein

Thursday, April 20, 2023

Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism
Lara Goldstein

Tuesday, February 21, 2023

Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Lara Goldstein

Tuesday, February 14, 2023

Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder
Lara Goldstein

Tuesday, December 27, 2022

First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval
Lara Goldstein

Tuesday, December 06, 2022

Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
Lara Goldstein

Wednesday, November 30, 2022

Psychedelic Partnership To Test Psilocybin For FXS In First Phase 2 Clinical Trial
Lara Goldstein

Thursday, November 17, 2022

Psychedelics For FXS Symptoms: New Research Contract For Upcoming Phase 2 Clinical Trial
Lara Goldstein

Friday, September 30, 2022

Psyched: Autopsy Reveals Death By Ketamine, LSD-Like Drugs Without Hallucinations, DEA & Right To Try Psilocybin
Lara Goldstein

Thursday, September 29, 2022

Magic Mushroom In A Pill? New Microdose Plans Enter Clinical Studies: Here's What Scientists Want To Learn
Lara Goldstein

Saturday, September 17, 2022

New Batch Of Psilocybin Microdose Capsules Is Ready, Learn All The Details
Lara Goldstein

Thursday, June 16, 2022

More Patent Applications For Psilocybin: Learn About NOVA's Psychedelic Treatments For Neurological Diseases
Lara Goldstein

Wednesday, June 08, 2022

Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies
Natan Ponieman

Tuesday, June 07, 2022

Nova Mentis NM-1001 Psilocybin Compound Gets DEA Approval For Export, Here's What Happened
Lara Goldstein

Thursday, April 07, 2022

Nova Mentis Is Looking To Treat Autism With Psilocybin
Fermin Orgambide

Tuesday, February 22, 2022

Psyched: Psilocybin Therapy Effective After One Year, Cybin & Deepak Chopra, Enveric Psilocybin Cancer Study
Natan Ponieman

Wednesday, February 16, 2022

This Psychedelics Penny Stock Is Up 55% After Successful Study On Microdosing For Autism
Aaron Bry

Tuesday, February 08, 2022

Wellbeing Digital Sciences' Integrated Approach Aims To Capture Emerging Mental Health Tech And Psychedelics Market
Rachael Green - Sponsored

Thursday, January 27, 2022

Wellbeing Digital Sciences' Subsidiary KGK Science Forms Tactical Partnership With Nova Mentis
Wellbeing Digital Sciences - Sponsored

Monday, November 08, 2021

Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
Natan Ponieman

Tuesday, October 26, 2021

Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent
Natan Ponieman

Monday, October 18, 2021

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
Natan Ponieman

Wednesday, October 13, 2021

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Natan Ponieman

Tuesday, April 06, 2021

Psyched: MindMed's 2020 Financials, Psychedelics ETF Rebalancing, Country's First Psychedelics Masters Degree
Natan Ponieman

Popular Channels

PreMarket Playbook
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved